These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16546667)

  • 21. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
    Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
    Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention.
    Tam CW; Mo CW; Yao KM; Shiu SY
    J Pineal Res; 2007 Mar; 42(2):191-202. PubMed ID: 17286752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GnRH antagonists in the treatment of advanced prostate cancer.
    Pommerville PJ; de Boer JG
    Can J Urol; 2010 Apr; 17(2):5063-70. PubMed ID: 20398443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells.
    Kim DK; Yang JS; Maiti K; Hwang JI; Kim K; Seen D; Ahn Y; Lee C; Kang BC; Kwon HB; Cheon J; Seong JY
    Cancer Res; 2009 Feb; 69(3):923-31. PubMed ID: 19176390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
    Fister S; Günthert AR; Emons G; Gründker C
    Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and neoplastic rat prostates.
    Lau HL; Zhu XM; Leung PC; Chan LW; Chen GF; Chan PS; Yu KL; Chan FL
    Int J Oncol; 2001 Dec; 19(6):1193-201. PubMed ID: 11713589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone inhibitors in prostate cancer: a systematic analysis.
    Schmid HP; Gregorin J; Altwein JE
    Urol Int; 2008; 81(1):17-22. PubMed ID: 18645266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.
    Limonta P; Manea M
    Cancer Treat Rev; 2013 Oct; 39(6):647-63. PubMed ID: 23290320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs.
    Winkel CA
    Postgrad Med; 1994 May; 95(6):111-8. PubMed ID: 8170869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid by gonadotropins in human immortalized ovarian surface epithelium and ovarian cancer cells.
    Choi JH; Choi KC; Auersperg N; Leung PC
    Endocr Relat Cancer; 2006 Jun; 13(2):641-51. PubMed ID: 16728589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone receptor-mediated growth suppression of immortalized LbetaT2 gonadotrope and stable HEK293 cell lines.
    Miles LE; Hanyaloglu AC; Dromey JR; Pfleger KD; Eidne KA
    Endocrinology; 2004 Jan; 145(1):194-204. PubMed ID: 14551223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
    Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
    Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gn-RH agonists in the treatment of prostatic carcinoma.
    Vacher P
    Biomed Pharmacother; 1995; 49(7-8):325-31. PubMed ID: 8562857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
    Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-releasing hormone in the ovary.
    Metallinou C; Asimakopoulos B; Schröer A; Nikolettos N
    Reprod Sci; 2007 Dec; 14(8):737-49. PubMed ID: 18089592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of gonadotropin-releasing hormone in nonhypothalamic tissues.
    Kim HH; Mui KL; Nikrodhanond AA; Tamayo NC
    Semin Reprod Med; 2007 Sep; 25(5):326-36. PubMed ID: 17710728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Yu S; Wang X; Ng CF; Chen S; Chan FL
    Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells.
    Hoda MR; Popken G
    BJU Int; 2008 Aug; 102(3):383-8. PubMed ID: 18341625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.